Loading...

COYA COYA THERAPEUTICS INC Investments/Divestments 8-K Filing

CY T

CY

COYA THERAPEUTICS INC

(COYA)

2023 8-K

Summary

Summary

Stock Offering Launch

Milestone Payment

Clinical Trials

Clinical Trials

Earnings Releases

Financial Results

Quarterly Results

Director Resignation

Management Changes

Clinical Trial Results

Management Change

Quarterly Results

Other Special Situation

Agreement Amendment

Securities Purchase Agreement

Earnings Reports

Results of Operations and F...

Quantitative Data

Development and License Agr...

Results of Operations and F...

Earnings Report

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Earnings Reports

Earnings Reports

License Agreement with Dr. ...

Conference Call for ALS Cli...

Banking Relationship

Equity Compensation Grants

External Links:

Coya Therapeutics entered into an exclusive License and Supply Agreement with Dr. Reddy's Laboratories for the development and commercialization of COYA 302, a biologic combination product candidate for neurodegenerative diseases.

AI Assistant

COYA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.